Compare ELSE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | INAB |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 14.2M |
| IPO Year | 1995 | 2020 |
| Metric | ELSE | INAB |
|---|---|---|
| Price | $4.37 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 4.2K | ★ 71.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $10,142,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.78 | ★ N/A |
| Revenue Growth | ★ 8.20 | N/A |
| 52 Week Low | $3.65 | $0.12 |
| 52 Week High | $5.29 | $4.20 |
| Indicator | ELSE | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 39.31 |
| Support Level | $4.08 | $1.35 |
| Resistance Level | $4.45 | $2.14 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 45.45 | 22.22 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.